Lorukafusp alfa

• Description:

  Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity[1].

• Product Name Alternative:

  APN-301; hu14.18-IL2; EMD 273063

• UNSPSC:

  12352203

• Target:

  Others

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lorukafusp-alfa.html

• Purity:

  97.8

• Solubility:

  10 mM in DMSO

• Smiles:

  [Lorukafuspalfa]

• Molecular Weight:

  (175.6 kDa)

• References & Citations:

  [1]Suzanne Shusterman, et al. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 Oct 15;25 (20) :6044-6051.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• CAS Number:

  [2131168-99-3]